% | $
Quotes you view appear here for quick access.

Lpath Inc. Message Board

  • jamess.reed jamess.reed May 5, 2014 8:17 AM Flag

    Lpath Lands Fast-Track SBIR Grant from the NIH for Traumatic Brain Injury Treatment

    SAN DIEGO, May 5, 2014 /PRNewswire/ -- Lpath, Inc. (LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the National Institutes of Neurological Diseases and Stroke (NINDS) that it has been awarded a $1.7 million, 2.5-year grant to develop its antibody therapeutic, Lpathomab™, which is directed against the bioactive lipid lysophosphatidic acid (LPA) for the treatment of traumatic brain injury (TBI).

    The Phase l amount of $224,000 will fund studies designed to repeat in rats the efficacy previously demonstrated (several times in mice) in a controlled-cortical-impact model of TBI. Contingent on Phase I success, Phase II funds of almost $1.5 million will be used to advance Lpathomab through safety, pharmacology, and toxicology studies needed to file an IND.

    My question is, why is this a 2.5 year grant when they are already planning to have a IND in early 2015?
    DOD is supposed to be testing mice in a blast injury model now, then sheep, then monkeys.
    If they replicate the mouse studies in a the cortical impact model for the NIH, do they then have to do more work with the 1.5 million, separate from the DOD work? Good time for a CC.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
2.88+0.10(+3.60%)Oct 21 4:00 PMEDT